A phase III trial of medications for castration resistance in metastatic prostate cancer
This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
This research study is led by Dr. Leslie Howard.
Contact: Dawn DeMarinis, 413-794-4362
January 01, 2014
Cancer - Prostate,
- D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
Baystate Franklin Medical Center, 164 High Street, Greenfield, MA
Participants must have progressive castration-resistant metastatic prostate cancer and rising PSA levels.
Interventional (Clinical Trial), Randomized